Product Description
Mechanisms of Action: Immunosuppressive Immuno
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Procter and Gamble
Company Location: CINCINNATI OH 45202
Company CEO: Jon R. Moeller
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|